JW Pharmaceutical relocates US research center from Seattle to Boston

JW Pharmaceutical announced on Wednesday that it has relocated its US research center to Boston from San Diego. 

JW Theriac was first established in Seattle in 2000 for chemical and genomics research. It moved the location to San Diego in 2018 and revamped its role as the point of contact for JW Group’s Open Innovation overseas strategy.

The relocation signals the pharmaceutical giant’s plans to strengthen its communications by joining the biggest bio cluster in the US. 

Based on JW Theriac’s research and development (R&D), the company will conduct research on clinical trials and technology transfers. 

Boston has emerged as the No. 1 bio cluster in the United States, with global pharmaceutical companies and bio startups setting up headquarters and research centers there. Around 1,000 pharmaceutical and biotech companies are based in Boston. 

The Chief Technology Officer (CTO) of JW Group Park Chan-hee said, “JW Theriac will serve as the focal point for the group’s global innovation strategy.” 

JW Pharmaceutical is currently conducting joint research with seven biotech companies in Korea and hopes to expand such efforts beyond the peninsula.

Write to Jung-Eun Kim at likesmile@hankyung.com
Jee Abbey Lee edited this article.